Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
19
05
2021
accepted:
09
08
2021
revised:
05
08
2021
pubmed:
23
8
2021
medline:
1
12
2022
entrez:
22
8
2021
Statut:
ppublish
Résumé
To systematically review and analyse the associations between fat and muscle mass measures with overall survival in men with prostate cancer. A systematic search was conducted in CINAHL, Cochrane Library, EMBASE, PubMed, and Web of Science databases from inception to December 2020, while abstracts from the American Society of Clinical Oncology (ASCO), Clinical Oncology Society of Australia (COSA), and the American College of Sports Medicine (ACSM) conferences were searched from 2014 to 2020. Eligible articles examined the association of body composition measures, such as fat mass (e.g., fat mass, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and VAT/SAT) and muscle mass measures, with overall survival in prostate cancer patients at any treatment stage. The primary endpoint was overall survival. Random-effect meta-analysis was conducted for studies reporting multivariable or univariable analysis assessing the associations of fat mass measures (i.e., fat mass, VAT, SAT, VAT/SAT) and muscle mass measures with overall survival. Sixteen cohort studies that comprised 4807 men with prostate cancer were included. Total adiposity (hazard ratio (HR) 0.98, 95% CI: 0.75-1.28, p = 0.888) and VAT (HR 1.03, 95% CI: 0.74-1.43, p = 0.873) were not significantly associated with overall survival, while higher subcutaneous adipose tissue levels were associated with higher survival (HR 0.68, 95% CI: 0.54-0.84, p = 0.001). Greater mortality risk was found in patients with localised (HR 1.91, 95% CI: 1.40-2.62, p < 0.001) and advanced disease (HR 1.43, 95% CI: 1.07-1.92, p = 0.020) presenting with low levels of muscle mass compared to those presenting with high levels. These results indicate that although overall adiposity should be cautiously interpreted in regards to survival, high muscle mass and SAT, and low VAT/SAT ratio values are associated with overall survival in men with prostate cancer.
Sections du résumé
BACKGROUND
To systematically review and analyse the associations between fat and muscle mass measures with overall survival in men with prostate cancer.
METHODS
A systematic search was conducted in CINAHL, Cochrane Library, EMBASE, PubMed, and Web of Science databases from inception to December 2020, while abstracts from the American Society of Clinical Oncology (ASCO), Clinical Oncology Society of Australia (COSA), and the American College of Sports Medicine (ACSM) conferences were searched from 2014 to 2020. Eligible articles examined the association of body composition measures, such as fat mass (e.g., fat mass, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and VAT/SAT) and muscle mass measures, with overall survival in prostate cancer patients at any treatment stage. The primary endpoint was overall survival. Random-effect meta-analysis was conducted for studies reporting multivariable or univariable analysis assessing the associations of fat mass measures (i.e., fat mass, VAT, SAT, VAT/SAT) and muscle mass measures with overall survival.
RESULTS
Sixteen cohort studies that comprised 4807 men with prostate cancer were included. Total adiposity (hazard ratio (HR) 0.98, 95% CI: 0.75-1.28, p = 0.888) and VAT (HR 1.03, 95% CI: 0.74-1.43, p = 0.873) were not significantly associated with overall survival, while higher subcutaneous adipose tissue levels were associated with higher survival (HR 0.68, 95% CI: 0.54-0.84, p = 0.001). Greater mortality risk was found in patients with localised (HR 1.91, 95% CI: 1.40-2.62, p < 0.001) and advanced disease (HR 1.43, 95% CI: 1.07-1.92, p = 0.020) presenting with low levels of muscle mass compared to those presenting with high levels.
DISCUSSION
These results indicate that although overall adiposity should be cautiously interpreted in regards to survival, high muscle mass and SAT, and low VAT/SAT ratio values are associated with overall survival in men with prostate cancer.
Identifiants
pubmed: 34420038
doi: 10.1038/s41391-021-00442-0
pii: 10.1038/s41391-021-00442-0
pmc: PMC9705235
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
615-626Informations de copyright
© 2021. The Author(s).
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
doi: 10.3322/caac.21442
D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289–95.
doi: 10.1001/jama.299.3.289
Prencipe M, Madden SF, O’Neill A, O’Hurley G, Culhane A, O’Connor D, et al. Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target? Prostate. 2013;73:743–53.
doi: 10.1002/pros.22618
Lin T-T, Chen Y-H, Wu Y-P, Chen S-Z, Li X-D, Lin Y-Z, et al. Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients. J Cancer. 2019;10:5608–13.
doi: 10.7150/jca.30731
Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102:44–7.
doi: 10.1111/j.1464-410X.2008.07539.x
Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30:3271–6.
doi: 10.1200/JCO.2011.38.8850
Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–92.
doi: 10.1111/j.1742-1241.2011.02799.x
Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Philos). 2011;4:486–501.
doi: 10.1158/1940-6207.CAPR-10-0229
Troeschel AN, Hartman TJ, Jacobs EJ, Stevens VL, Gansler T, Flanders WD, et al. Postdiagnosis body mass index, weight change, and mortality from prostate cancer, cardiovascular disease, and all causes among survivors of nonmetastatic prostate cancer. J Clin Oncol. 2020;38:2018–27.
doi: 10.1200/JCO.19.02185
Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA. Obesity, inflammation, and cancer. Annu Rev Pathol. 2016;11:421–49.
doi: 10.1146/annurev-pathol-012615-044359
Wiltz AL, Shikanov S, Eggener SE, Katz MH, Thong AE, Steinberg GD, et al. Robotic radical prostatectomy in overweight and obese patients: oncological and validated-functional outcomes. Urology. 2009;73:316–22.
doi: 10.1016/j.urology.2008.08.493
Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol. 2005;174:1798–801.
doi: 10.1097/01.ju.0000177077.53037.72
Mikhail AA, Stockton BR, Orvieto MA, Chien GW, Gong EM, Zorn KC, et al. Robotic-assisted laparoscopic prostatectomy in overweight and obese patients. Urology. 2006;67:774–9.
doi: 10.1016/j.urology.2005.10.049
Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM. Anthropometric measurements and survival after a prostate cancer diagnosis. Br J Cancer. 2018;118:607–10.
doi: 10.1038/bjc.2017.440
Zhong S, Yan X, Wu Y, Zhang X, Chen L, Tang J, et al. Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis. Prostate Cancer Prostatic Dis. 2016;19:122–31.
doi: 10.1038/pcan.2015.64
Xu MC, Huelster HL, Hatcher JB, Avulova S, Stocks BT, Glaser ZA, et al. Obesity is associated with longer survival independent of sarcopenia and myosteatosis in metastatic and/or castrate-resistant prostate cancer. J Urol. 2021;205:800–5.
doi: 10.1097/JU.0000000000001428
Brown JC, Cespedes Feliciano EM, Caan BJ. The evolution of body composition in oncology-epidemiology, clinical trials, and the future of patient care: facts and numbers. J Cachexia Sarcopenia Muscle. 2018;9:1200–8.
doi: 10.1002/jcsm.12379
Flegal KM, Shepherd JA, Looker AC, Graubard BI, Borrud LG, Ogden CL, et al. Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr. 2009;89:500–8.
doi: 10.3945/ajcn.2008.26847
Lee DH, Giovannucci EL. The obesity paradox in cancer: epidemiologic insights and perspectives. Curr Nutr Rep. 2019;8:175–81.
doi: 10.1007/s13668-019-00280-6
Marshall CH, Joshu CE. Mounting weight of evidence on the importance of body weight for men with prostate cancer. J Clin Oncol. 2020;38:2007–9.
doi: 10.1200/JCO.20.00791
Ubachs J, Ziemons J, Minis-Rutten IJG, Kruitwagen R, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10:1165–74.
doi: 10.1002/jcsm.12468
Lee CM, Kang J. Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2020;11:1270–82.
doi: 10.1002/jcsm.12575
Antoniou GA, Rojoa D, Antoniou SA, Alfahad A, Torella F, Juszczak MT. Effect of low skeletal muscle mass on post-operative survival of patients with abdominal aortic aneurysm: a prognostic factor review and meta-analysis of time-to-event data. Eur J Vasc Endovasc Surg. 2019;58:190–8.
doi: 10.1016/j.ejvs.2019.03.020
Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, Di Palma M, et al. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer. 2015;51:2570–7.
doi: 10.1016/j.ejca.2015.07.042
Pak S, Park SY, Shin TJ, You D, Jeong IG, Hong JH, et al. Association of muscle mass with survival after radical prostatectomy in patients with prostate cancer. J Urol. 2019;202:525–32.
doi: 10.1097/JU.0000000000000249
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T, Mulrow CD, et al. Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines. J Clin Epidemiol. 2020;118:60–8.
doi: 10.1016/j.jclinepi.2019.11.010
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3:e123–30.
Furlan AD, Pennick V, Bombardier C, van Tulder M,Editorial Board CBRG. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Philos Pa 1976). 2009;34:1929–41.
doi: 10.1097/BRS.0b013e3181b1c99f
Scherer RW, Saldanha IJ. How should systematic reviewers handle conference abstracts? A view from the trenches. Syst Rev. 2019;8:264.
doi: 10.1186/s13643-019-1188-0
Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. Newcastle-Ottawa quality assessment scale cohort studies. University of Ottawa. 2014. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp2014 .
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
doi: 10.1136/bmj.327.7414.557
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61:991–6.
doi: 10.1016/j.jclinepi.2007.11.010
Buttigliero C, Vana F, Bertaglia V, Vignani F, Fiori C, Osella G, et al. The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome. Endocrine. 2015;50:223–30.
doi: 10.1007/s12020-015-0525-x
Wu W, Liu X, Chaftari P, Cruz Carreras MT, Gonzalez C, Viets-Upchurch J, et al. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. PLoS ONE. 2015;10:e0122047.
doi: 10.1371/journal.pone.0122047
Cushen SJ, Power DG, Murphy KP, McDermott R, Griffin BT, Lim M, et al. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. Clin Nutr Espen. 2016;13:e39–45.
doi: 10.1016/j.clnesp.2016.04.001
McDonald AM, Swain TA, Mayhew DL, Cardan RA, Bakder CB, Harris DM, et al. (S010) Computed tomography–assessed measures of bone mineral density and muscle mass as predictors of survival in men with prostate cancer. Oncology (08909091). 2016 Supplement A Century of Caring, p5-5. 1/2p.
Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, et al. The association between sarcopenia and oncologic outcomes after radical prostatectomy. Clin Genitourin Cancer. 2018;16:e629–36.
doi: 10.1016/j.clgc.2017.11.003
Zakaria HM, Massie L, Basheer A, Elibe E, Boyce-Fappiano D, Shultz L, et al. Application of morphometrics as a predictor for survival in patients with prostate cancer metastasis to the spine. World Neurosurg. 2018;114:e913–9.
doi: 10.1016/j.wneu.2018.03.115
Ohtaka A, Aoki H, Nagata M, Kanayama M, Shimizu F, Ide H, et al. Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy. Prostate Int. 2019;7:9–14.
doi: 10.1016/j.prnil.2018.04.002
Di Bella CM, Howard LE, Oyekunle T, De Hoedt AM, Salama JK, Song H, et al. Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy. Prostate. 2020;80:1244–52.
doi: 10.1002/pros.24054
Ikeda T, Ishihara H, Iizuka J, Hashimoto Y, Yoshida K, Kakuta Y, et al. Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. Jpn J Clin Oncol. 2020;50:933–9.
doi: 10.1093/jjco/hyaa045
Lee J, Park JS, Heo JE, Ahn HK, Jang WS, Ham WS, et al. Muscle characteristics obtained using computed tomography as prognosticators in patients with castration-resistant prostate cancer. Cancers. 2020;12:1864.
doi: 10.3390/cancers12071864
Pak S, Kim MS, Park EY, Kim SH, Lee KH, Joung JY. Association of body composition with survival and treatment efficacy in castration-resistant prostate cancer. Front Oncol. 2020;10:558.
doi: 10.3389/fonc.2020.00558
Sasaki T, Sugino Y, Kato M, Nishikawa K, Kanda H. Pre-treatment ratio of periprostatic to subcutaneous fat thickness on MRI is an independent survival predictor in hormone-naive men with advanced prostate cancer. Int J Clin Oncol. 2020;25:370–6.
doi: 10.1007/s10147-019-01559-y
Stangl-Kremser J, Suarez-Ibarrola R, Andrea D, Korn SM, Pones M, Kramer G, et al. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. Prostate Cancer Prostatic Dis. 2020;23:309–15.
doi: 10.1038/s41391-019-0186-6
Mukherji D, Pezaro CJ, Bianchini D, Tunariu N, Cassidy MA, Omlin AG, et al. Sarcopenia and altered body composition following abiraterone acetate (AA) and corticosteroid (C) treatment in men with castration-refractory prostate cancer (CRPC). J Clin Oncol Am Soc Clin Oncol. 2012;30(15_suppl):e15134–e15134.
Blauwhoff-Buskermolen S, Langius JAE, Becker A, Verheul HMW, de van der Schueren MAE. The influence of different muscle mass measurements on the diagnosis of cancer cachexia. J Cachexia Sarcopenia Muscle. 2017;8:615–22.
doi: 10.1002/jcsm.12200
Versteeg KS, Blauwhoff-Buskermolen S, Buffart LM, de van der Schueren MAE, Langius JAE, Verheul HMW, et al. Higher muscle strength is associated with prolonged survival in older patients with advanced cancer. Oncologist. 2018;23:580–5.
doi: 10.1634/theoncologist.2017-0193
Delouya G, Tiberi D, Bhatnagar SR, Campeau S, Saad F, Taussky D. Impact of adipose tissue on prostate cancer aggressiveness—analysis of a high-risk population. Horm Mol Biol Clin Investig. 2018;36:1–6.
Pennington Z, Pielkenrood B, Ahmed AK, Goodwin CR, Verlaan JJ, Sciubba DM. Visceral fat volume from standard preoperative ct is an independent predictor of short-term survival in patients undergoing surgery for metastatic spine disease. Clin Spine Surg. 2019;32:E303–10.
doi: 10.1097/BSD.0000000000000784
Zakaria HM, Llaniguez JT, Telemi E, Chuang M, Abouelleil M, Wilkinson B, et al. Sarcopenia predicts overall survival in patients with lung, breast, prostate, or myeloma spine metastases undergoing stereotactic body radiation therapy (SBRT), independent of histology. Neurosurgery. 2020;86:705–16.
doi: 10.1093/neuros/nyz216
Ebadi M, Martin L, Ghosh S, Field CJ, Lehner R, Baracos VE, et al. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 2017;117:148–55.
doi: 10.1038/bjc.2017.149
Ebadi M, Baracos VE, Bathe OF, Robinson LE, Mazurak VC. Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with n-6 fatty acid content. Clin Nutr. 2016;35:1347–53.
doi: 10.1016/j.clnu.2016.02.014
Porter SA, Massaro JM, Hoffmann U, Vasan RS, O’Donnel CJ, Fox CS. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care. 2009;32:1068–75.
doi: 10.2337/dc08-2280
Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, et al. Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology. 2009;136:1242–50.
doi: 10.1053/j.gastro.2008.12.048
Lee JS, Lee HS, Ha JS, Han KS, Rha KH, Hong SJ, et al. Subcutaneous fat distribution is a prognostic biomarker for men with castration resistant prostate cancer. J Urol. 2018;200:114–20.
doi: 10.1016/j.juro.2018.01.069
Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71–82.
doi: 10.1001/jama.2012.113905
Uchida T, Higure T, Kawakami M, Nakano M, Nakajima N, Kim H, et al. What factors affect the operative time of robot-assisted laparoscopic radical prostatectomy? Surg Endosc. 2020;35:4436–43.
Karlsson T, Rask-Andersen M, Pan G, Höglund J, Wadelius C, Ek WE, et al. Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease. Nat Med. 2019;25:1390–5.
doi: 10.1038/s41591-019-0563-7
Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: the emerging roles of myokines. Endocr Rev. 2020;41:594–609.
doi: 10.1210/endrev/bnaa016
Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8:457–65.
doi: 10.1038/nrendo.2012.49
Sartori R, Romanello V, Sandri M. Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat Commun. 2021;12:330.
doi: 10.1038/s41467-020-20123-1
Lopez P, Taaffe DR, Newton RU, Galvao DA. Resistance exercise dosage in men with prostate cancer: systematic review, meta-analysis, and meta-regression. Med Sci Sports Exerc. 2021;53:459–69.
doi: 10.1249/MSS.0000000000002503
Newton RU, Galvao DA, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients. Med Sci Sports Exerc. 2019;51:607–14.
doi: 10.1249/MSS.0000000000001831
Taaffe DR, Galvao DA, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition. BJU Int. 2019;123:261–9.
doi: 10.1111/bju.14505
Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28:340–7.
doi: 10.1200/JCO.2009.23.2488
Galvao DA, Taaffe DR, Spry N, Cormie P, Joseph D, Chambers SK, et al. Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc. 2018;50:393–9.
doi: 10.1249/MSS.0000000000001454
Williams GR, Dunne RF, Giri S, Shachar SS, Caan BJ. Sarcopenia in the Older Adult With Cancer. J Clin Oncol. 2021;39:2068–78.